Physician profile
Aisha Khan
NPI 1265939540
$1,345.43
in general payments reported to CMS, 2019-2025
16 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.46 · 2022: $87.81 · 2024: $638 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $291.00 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $195.64 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $185.44 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.06 | 2022-2025 | Breztri, Farxiga |
| Exact Sciences Corporation | $90.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $85.99 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $83.94 | 2024-2025 | Veozah |
| Intra-Sana Laboratories | $57.41 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.08 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $44.71 | 2022-2025 | Eliquis |
| Pfizer INC. | $36.12 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.35 | 2024 | Trintellix |
| Eisai INC. | $19.94 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $19.68 | 2024 | Baqsimi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2024 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $13.95 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.